News

India’s Pharma Sector Enters Pivotal Phase as It Eyes Innovation-Led Growth Towards USD 500 Billion Ambition

India’s pharmaceutical industry is poised at a critical juncture as it heads into 2026, marking the start of a decisive five-year period aimed at transforming the nation into a global innovation hub and pushing toward a USD 500 billion valuation by 2047.

• By Newsdesk
• New Delhi
• Dec 22, 2025

News

India’s pharmaceutical industry is poised at a critical juncture as it heads into 2026, marking the start of a decisive five-year period aimed at transforming the nation into a global innovation hub and pushing toward a USD 500 billion valuation by 2047. 

Historically driven by generics, India’s drug sector has expanded dramatically—from a modest USD 3 billion a quarter-century ago to approximately USD 60 billion today. But with a wave of high-value medicines soon losing patent protection, industry leaders see a strategic opening to pivot toward next-generation therapies and research-intensive products. 

“A defining moment for Indian pharma”

Sudarshan Jain, Secretary-General of the Indian Pharmaceutical Alliance (IPA), said the industry now stands at a watershed moment. He emphasised that the next five years will be crucial for converting favourable policy momentum into tangible advancements that support India’s long-term growth and innovation objectives. 

The recent rollout of the Promotion of Research and Innovation in Pharma MedTech (PRIP) initiative and a new Research Development Incentive Scheme, particularly focused on bio-manufacturing has drawn strong industry response, signalling a shift from volume-based growth to value creation. 

Leading Indian manufacturers are already aligning with this vision, bolstering their portfolios with higher-value products, securing global regulatory approvals, and entering strategic licensing agreements. 

Global challenges and ecosystem building

While Indian firms navigate external headwinds such as tariff volatility and changing global trade patterns, the industry is doubling down on strengthening its manufacturing resilience, quality standards, and intellectual property protections. These factors, industry bodies argue, are critical to attracting sustained investments and integrating more deeply with international markets. 

Speaking for the Organisation of Pharmaceutical Producers of India (OPPI), Director-General Anil Matai underscored that placing quality, IP confidence, and innovation at the forefront will help shift the industry’s competitive edge beyond cost-led advantages. 

Healthcare and MedTech optimism

The focus on innovation extends beyond drugs to the broader healthcare landscape. NATHEALTH President Ameera Shah highlighted that as key therapies lose exclusivity and care models evolve, 2026 must be about execution, turning technological potential into measurable improvements in health outcomes and equitable access. 

In the MedTech arena, industry executives pointed to recent policy reforms—such as GST changes—as catalysts energising growth. Leaders like Philips India’s MD Bharath Sesha and Poly Medicure’s Himanshu Baid emphasised the importance of long-term investment in R&D, localisation of critical components, and faster clinical validation for advanced technologies. 

As the Indian pharmaceutical and healthcare sectors embark on this ambitious journey, collective action, forward-looking policies, and a steadfast commitment to innovation are seen as the pillars that will help the industry compete on the global stage while expanding access to high-quality, cutting-edge treatments worldwide. 

(Source: PTI)